Page last updated: 2024-08-05 12:15:06

naphthalenecarboxamide

Any member of the class of naphthalenes in which the naphthalene ring is directly attached to the carbonyl carbon of a carboxamide group.

ChEBI ID: 48739

Members (24)

MemberDefinitionRole
1-methoxy-N-[4-(pyridin-4-ylmethyl)phenyl]-2-naphthalenecarboxamide1-methoxy-N-[4-(pyridin-4-ylmethyl)phenyl]-2-naphthalenecarboxamide
2-naphthylamideA naphthalenecarboxamide resulting from the formal condensation of the carboxy group of 2-naphthoic acid with ammonia.naphthalene-2-carboxamide
3-[2-(2-furanylmethylamino)-2-oxoethoxy]-N-(2-methoxy-5-methylphenyl)-2-naphthalenecarboxamide3-[2-(2-furanylmethylamino)-2-oxoethoxy]-N-(2-methoxy-5-methylphenyl)-2-naphthalenecarboxamide
3-methoxy-N-(5-methyl-2-pyridinyl)-2-naphthalenecarboxamide3-methoxy-N-(5-methyl-2-pyridinyl)-2-naphthalenecarboxamide
3-methoxy-N-[2-(4-methoxyphenyl)-2-(1-pyrrolidinyl)ethyl]-2-naphthalenecarboxamide3-methoxy-N-[2-(4-methoxyphenyl)-2-(1-pyrrolidinyl)ethyl]-2-naphthalenecarboxamide
5-(1,3-benzodioxol-5-ylmethyl)-4-methyl-2-[[1-naphthalenyl(oxo)methyl]amino]-3-thiophenecarboxamide5-(1,3-benzodioxol-5-ylmethyl)-4-methyl-2-[[1-naphthalenyl(oxo)methyl]amino]-3-thiophenecarboxamide
6-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]-2-[3-(trifluoromethyl)phenyl]benzo[de]isoquinoline-1,3-dione6-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]-2-[3-(trifluoromethyl)phenyl]benzo[de]isoquinoline-1,3-dione
bp 897N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-2-naphthalenecarboxamide
bunaftinebunaftine
lucitanibA naphthalenecarboxamide obtained from formal condensation of the carboxy group of aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)-1-naphthoic acid with methylamine.E-3810 free base
N-(2-methyl-1,3-dioxo-5-isoindolyl)-1-naphthalenecarboxamideN-(2-methyl-1,3-dioxo-5-isoindolyl)-1-naphthalenecarboxamide
N-(2-methyl-5-tetrazolyl)-2-naphthalenecarboxamideN-(2-methyl-5-tetrazolyl)-2-naphthalenecarboxamide
N-(2,2,2-trichloro-1-diethoxyphosphorylethyl)-1-naphthalenecarboxamideN-(2,2,2-trichloro-1-diethoxyphosphorylethyl)-1-naphthalenecarboxamide
N-(3-acetylphenyl)-2-naphthalenecarboxamideN-(3-acetylphenyl)-2-naphthalenecarboxamide
N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamideN-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide
N-(4-ethoxyphenyl)-3-hydroxy-2-naphthalenecarboxamideN-(4-ethoxyphenyl)-3-hydroxy-2-naphthalenecarboxamide
N-(4-hydroxyphenyl)-3-methoxy-2-naphthalenecarboxamideN-(4-hydroxyphenyl)-3-methoxy-2-naphthalenecarboxamide
N-[[5-(1,3-benzothiazol-2-yl)-2-methylanilino]-sulfanylidenemethyl]-1-naphthalenecarboxamideN-[[5-(1,3-benzothiazol-2-yl)-2-methylanilino]-sulfanylidenemethyl]-1-naphthalenecarboxamide
N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamideN-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide
N-[4-(1-pyrrolidinyl)phenyl]-2-naphthalenecarboxamideN-[4-(1-pyrrolidinyl)phenyl]-2-naphthalenecarboxamide
N-[5-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-1-naphthalenecarboxamideN-[5-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-1-naphthalenecarboxamide
N-tert-butyl-1,2-dihydroacenaphthylene-5-carboxamideN-tert-butyl-1,2-dihydroacenaphthylene-5-carboxamide
nafadotrideA naphthalenecarboxamide resulting from the formal condensation of the carboxylic acid group of 4-cyano-1-methoxynaphthalene-2-carboxylic acid with the primary amino group of 1-(1-butylpyrrolidin-2-yl]methanamine. It is a highly potent, competitive, preferential dopamine D3 receptor antagonist, centrally active upon systemic administration.nafadotride
orteronel6-(7-hydroxy-5,6-dihydropyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide

Research

Studies (218)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-199031 (14.22)18.7374
1990's24 (11.01)18.2507
2000's84 (38.53)29.6817
2010's64 (29.36)24.3611
2020's15 (6.88)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials6 (1.80%)5.53%
Reviews11 (3.30%)6.00%
Case Studies1 (0.30%)4.05%
Observational0 (0.00%)0.25%
Other315 (94.59%)84.16%